Vivalis is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of viral diseases. Vivalis' s expertise and intellectual property are exploited in three main areas: The development and manufacturing of vaccines, the development of production systems for recombinant proteins and monoclonal antibodies, the construction of a portfolio of proprietary products in the area of vaccines and anti-viral molecules. Based in Nantes, Vivalis was created in 1999 by Group GRIMAUD. The business model of the company is to license its technologies and its products at pre-clinical or early clinical stages. The company became public as of July 31, 2007.